{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024675","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.472371+00:00","generated_at":"2026-06-21T20:24:38.617349+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cogent Biosciences Q3 net loss $35.1M; cash $289.1M, runway into 2025; Phase 3 PEAK trial started","bullets":["Net loss $35.1M vs $19.1M YoY; R&D expense $29.9M (up from $14.8M) due to trials and team expansion.","Cash & securities $289.1M as of Sep 30, 2022; cash runway expected into 2025.","Phase 3 PEAK trial of bezuclastinib + sunitinib in second-line GIST patients initiated.","Optimized bezuclastinib formulation shows >40% exposure improvement; potential patent protection to 2043.","G&A expense $6.9M vs $5.0M YoY; non-cash stock comp included."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024675","json":"https://secwatch.observer/filing/0000950170-22-024675.json","markdown":"https://secwatch.observer/filing/0000950170-22-024675.md","text":"https://secwatch.observer/filing/0000950170-22-024675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/0000950170-22-024675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/cogt-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:24:38.617349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df9c5dcff78947abe34d23a433c4d192a06bdbfc","claim":"Cogent Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $35.1 million.","evidence_excerpt":"Net Loss: Net loss was $35.1 million for the th","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/0000950170-22-024675-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$35.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}